WEKO3
アイテム
進行胃癌一次治療終了後における予後の延長:JCOG9205/JCOG9912統合解析
http://hdl.handle.net/10559/17183
http://hdl.handle.net/10559/17183c04a68b6-0667-4c0e-bca8-2334b01460ac
| Item type | デフォルトアイテムタイプ（フル）(1) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2023-04-17 | |||||||||||
| タイトル | ||||||||||||
| タイトル | Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology Group Trials JCOG9205 and JCOG9912 | |||||||||||
| 言語 | en | |||||||||||
| タイトル | ||||||||||||
| タイトル | 進行胃癌一次治療終了後における予後の延長:JCOG9205/JCOG9912統合解析 | |||||||||||
| 言語 | ja | |||||||||||
| 作成者 |
高島, 淳生
× 高島, 淳生
|
|||||||||||
| アクセス権 | ||||||||||||
| アクセス権 | metadata only access | |||||||||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||||||||
| 内容記述 | ||||||||||||
| 内容記述 | Background: Two randomized phase III trials of first-line chemotherapy for advanced gastric cancer (JCOG9205 and JCOG9912) conducted by the Japan Clinical Oncology Group used 5-fluorouracil continuous infusion (5-FUci) as the control arm. New active agents (e.g., S-1, irinotecan, and taxanes) were introduced as second-line chemotherapy in the late 1990s after JCOG9205. This combined analysis evaluated whether patients in the 5-FUci arm of JCOG9912 exhibited better survival after adjusting for baseline factors and also investigated the cause of survival prolongation. | |||||||||||
| 言語 | en | |||||||||||
| 内容記述 | ||||||||||||
| 内容記述 | Patients and methods: The subjects were patients assigned to the 5-FUci arms who met the eligibility criteria of both JCOG9205 and JCOG9912. Overall survival (OS), time to treatment failure (TTF), and survival after treatment failure in the first-line chemotherapy (OS-TTF) were compared after adjusting baseline characteristics using the Cox proportional hazard model. Second-line chemotherapy details were also reviewed. | |||||||||||
| 言語 | en | |||||||||||
| 内容記述 | ||||||||||||
| 内容記述 | Results: The combined analysis included 89 and 230 patients in JCOG9205 and JCOG9912, respectively. After adjusting baseline characteristics, TTF was similar between groups (HR 0.95; 95 % CI, 0.73-1.26). However, both OS (HR, 0.74; 95 % CI, 0.56-0.99) and OS-TTF (HR, 0.76; 95 % CI, 0.57-1.01) were longer in JCOG9912. More patients in JCOG9912 received second-line chemotherapy (83 vs. 52 %) with new drugs (77 vs. 10 %) than in JCOG9205. OS-TTF was substantially prolonged in patients who received second-line chemotherapy (HR, 0.66; 95 % CI, 0.46-0.95). | |||||||||||
| 言語 | en | |||||||||||
| 内容記述 | ||||||||||||
| 内容記述 | Conclusion: OS and OS-TTF were longer in JCOG9912 than JCOG9205. Second-line chemotherapy with new drugs is a potential reason for the observed prolongation of survival. | |||||||||||
| 言語 | en | |||||||||||
| 出版者 | ||||||||||||
| 出版者 | 大分大学 | |||||||||||
| 言語 | ja | |||||||||||
| 日付 | ||||||||||||
| 日付 | 2015-01-01 | |||||||||||
| 日付タイプ | Issued | |||||||||||
| 言語 | ||||||||||||
| 言語 | eng | |||||||||||
| 資源タイプ | ||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_db06 | |||||||||||
| 資源タイプ | doctoral thesis | |||||||||||
| 識別子 | ||||||||||||
| 識別子 | http://hdl.handle.net/10559/17183 | |||||||||||
| 識別子タイプ | HDL | |||||||||||
| 関連情報 | ||||||||||||
| 関連タイプ | isVersionOf | |||||||||||
| 識別子タイプ | DOI | |||||||||||
| 関連識別子 | https://doi.org/10.1007/s10120-013-0309-z | |||||||||||
| 学位授与番号 | ||||||||||||
| 学位授与番号 | 乙第334号 | |||||||||||
| 学位名 | ||||||||||||
| 言語 | ja | |||||||||||
| 学位名 | 博士(医学) | |||||||||||
| 学位授与年月日 | ||||||||||||
| 学位授与年月日 | 2015-06-29 | |||||||||||
| 学位授与機関 | ||||||||||||
| 言語 | ja | |||||||||||
| 学位授与機関名 | 大分大学 | |||||||||||
